At a glance
- Originator Pfizer
- Class Anti-ischaemics; Antiplatelets; Benzoic acids; Imidazoles; Vascular disorder therapies
- Mechanism of Action Thromboxane A2 synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ischaemic heart disorders; Thrombosis